View : 460 Download: 0
Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis
- Title
- Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis
- Authors
- Chun, Ho Soo; Choe, A. Reum; Lee, Minjong; Cho, Yuri; Kim, Hwi Young; Yoo, Kwon; Kim, Tae Hun
- Ewha Authors
- 유권; 김휘영; 이민종; 최아름; 전호수
- SCOPUS Author ID
- 유권; 김휘영; 이민종; 최아름; 전호수
- Issue Date
- 2021
- Journal Title
- CLINICAL AND MOLECULAR HEPATOLOGY
- ISSN
- 2287-2728
2287-285X
- Citation
- CLINICAL AND MOLECULAR HEPATOLOGY vol. 27, no. 4, pp. 535 - 552
- Keywords
- Anticoagulants; Portal vein; Thrombosis; Liver cirrhosis
- Publisher
- KOREAN ASSOC STUDY LIVER
- Indexed
- SCIE; SCOPUS; KCI
- Document Type
- Review
- Abstract
- Although patients with cirrhosis are known to be in a state of "rebalance" in that pro-and anticoagulant factors increase the risk for both bleeding and thrombosis, the prevalence of portal vein thrombosis (PVT) in patients with cirrhosis can be up to 26%. Therefore, physicians should consider anticoagulation for the prevention and management of PVT in patients with cirrhosis who are at high risk of PVT. Vitamin K antagonist or low molecular weight heparin is suggested as the standard treatment for PVT in cirrhosis. With the advent of new direct-acting oral anticoagulants (DOACs), there is a paradigm shift of switching to DOACs for the treatment of PVT in patients with cirrhosis. However, the safety and efficacy of DOACs in the treatment of PVT was not well-known in patients with cirrhosis. Therefore, this review focused on the current knowledge about the efficacy, safety concerns, and hepatic metabolism of DOACs in patients with cirrhosis and PVT. (Clin Mol Hepatol 2021;27:535-552)
- DOI
- 10.3350/cmh.2021.0109
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML